JEAN-FRANÇOIS TREMBLAY/C&EN
BUSINESS
FDA STRUGGLES TO KEEP UP IN INDIA Facility INSPECTIONS ARE DECLINING in the country that supplies the most generic drugs to the U.S. JEAN-FRANÇOIS TREMBLAY, C&EN HONG KONG
WHEN STRATIVA Pharmaceuticals an-
nounced in February that it could not launch a new product, the only reason, the New Jersey-based firm said in a statement, was that the U.S. Food & Drug Administration had not inspected the plant in India where the drug was to be made because of “an agencywide restriction on foreign travel to India.” A record obtained by C&EN of FDA’s inspections of Indian pharmaceutical facilities during the past several months reveals a sharp drop from December through March, although not a complete halt. The record raises new questions about the consistency and adequacy of the agency’s audits in India. A long-lasting drop in the number of inspections that FDA performs in India would significantly affect the U.S. drug supply. In recent years, India has become the largest foreign supplier of generic drugs to the U.S., with 410 plants producing drug ingredients and drugs in finisheddosage forms.
India-based FDA staff were free to go to all parts of the country. Strativa did not respond to C&EN’s request to explain its allegation regarding FDA travel to India. However, when the firm’s parent, Par Pharmaceutical Cos., posted its fourth-quarter results in late February, it said FDA had “lifted” its restrictions on travel to India. A 2008 report by the Government Accountability Office (GAO), the investigative
Without plant inspecWANING AUDITS tions, new drugs or cheap U.S. FDA performed surprisingly few plant generics made in India caninspections from December 2009 to March 2010 not be approved for sale in the U.S. Moreover, without DECEMBER—MARCH NOVEMBER—MAY periodic inspections of NO. OF PLANT INSPECTIONS 2008–09 2009–10 2008–09 2009–10 existing operations, FDA U.S.-based inspectors 22 5 44 31 India-based inspectors 4 9 4 10 cannot know whether manufacturers that have TOTAL 26 14 48 41 been approved are sticking to the high manufacturNOTE: The U.S. Food & Drug Administration opened an office in India in January 2009. ing standards that initially SOURCE: U.S. Food & Drug Administration (through a Freedom of Informaearned them the agency’s tion Act request) green light. “There is not now, and there has not been, any recent FDA-imposed arm of Congress, brought to light deficiennationwide travel restriction to India recies in FDA’s foreign inspection program. It garding the FDA’s personnel traveling to concluded that FDA needs to conduct more or in India,” FDA press officer Rita Chapforeign inspections, keep better records pelle told C&EN in February in response to about inspections than it has been doing so Strativa’s claim that FDA was not sending far, and promptly conduct follow-up inspecinspectors to India. She added that FDA tions after it uncovers serious violations trips were continuing as usual and that (C&EN, Nov. 3, 2008, page 17). David Moore, chief strategy officer at New Jersey-based ChemWerth, tells C&EN that it’s not only plants in India that should be inspected more often. “FDA is woefully underfunded and besieged with applica-
“FDA is woefully underfunded and besieged with applications and requests worldwide.” WWW.CEN-ONLINE.ORG
28
JUNE 14, 2010
RediSep Rf Gold™ UP TO SNUFF Part of an FDA-approved
Proven Purity.
facility making active pharmaceutical ingredients in Hyderabad, India. The agency normally revisits plants that it has approved every few years.
tions and requests worldwide.” He adds that foreign manufacturers need a strong U.S. representative to help them avoid unexpected regulatory problems in the U.S. market. ChemWerth is the exclusive agent for numerous Chinese and Indian manufacturers. But according to Peter Saxon, a New Jersey-based consultant to pharmaceutical manufacturers preparing for FDA inspections, who presently has 17 customers on the subcontinent, “There is definitely something wrong with the FDA’s schedule of inspections in India.”
Standard (irregular media) Flash Chromatography Column
RediSep Rf Gold Column
No baseline resolution. Impure compound.
Baseline resolution. Pure compound.
(spherical media)
C&EN OBTAINED FDA’s records of visits
in India through a Freedom of Information Act request for the logs of inspections performed by FDA in India for the period from December 2009 to March 2010 and the corresponding year-earlier period. FDA responded with a detailed record of inspections of Indian manufacturing facilities by U.S.-based inspectors during two sevenmonth periods: from November 2008 to May 2009 and from November 2009 to May 2010. In addition, the agency handed over its logs of inspections performed by Indiabased inspectors during 2009 and 2010. FDA opened an office in India in January 2009. The logs confirm that FDA sharply curtailed its inspections of India in early 2010. From December 2009 to March 2010, U.S.-based manufacturing investigators conducted only five inspections in India compared with 22 one year earlier. During the same period, India-based inspectors visited nine plants, compared with four one year earlier. Overall, the agency conducted 14 inspections in India in the four-month period, compared with 26 one year earlier. Over the two seven-month periods for which FDA provided data, however, the drop in inspections was not as sharp. Between November 2009 and May 2010, U.S.-based FDA inspectors conducted 31 audits in India, compared with 44 one year earlier. Meanwhile, India-based inspectors conducted 10 inspections compared with four in the same period one year before. Overall, FDA conducted 41 inspections in the seven months through May 2010, compared with 48 one year earlier. Although this decline is more modest than
The sharper peaks (shown above) can be obtained on highly polar compounds by using RediSep Gold High-performance flash chromatography columns. Our patented* spherical silica utilizes small particle sizes (20-40µm), and gives you: Better separations Faster run times Higher loads Reduced solvent usage * Foreign Patent granted, U.S. Patent pending.
Tight spherical packing Request a sample and see the
gives you best-in-industry
Gold performance for yourself!
separation for high
www.isco.com/rfgold
polarity compounds.
800.228.4373 • 402.464.0231 • www.isco.com •
[email protected] WWW.CEN-ONLINE.ORG
29
JUNE 14, 2010
ACS Member
Insurance Program
Giving you access to the plan options you need to help safeguard you and your family: t Group 10-Year Level Term*:3BUFTHVBSBOUFFEGPS BZFBSUFSN VQUP PGDPWFSBHF t Group Term Life*:6QUP JODPWFSBHF t Group Hospital Indemnity*: 1BZTVQUPB EBZXIFOZPVSFIPTQJUBMJ[FE t Group Disability Income*: 3FQMBDFTVQUPPGZPVS NPOUIMZTBMBSZ VQUP BNPOUI t Group Accidental Death & Dismemberment*: 1SPWJEFTVQUP JODBTFPGBOBDDJEFOUBMEFBUI PSJOKVSZ BDDFQUBODFJTHVBSBOUFFE t Long Term Care:)FMQTXJUIFYQFOTJWFTLJMMFE DBSFOFFET BUIPNFPSJOBGBDJMJUZ XIJMFQSPUFDUJOH ZPVSBTTFUT t Supplemental Health Plans:5BLFTPWFSXIFO ZPVSCBTJDIFBMUIJOTVSBODFSVOTTIPSU t Professional Liability: $VTUPNEFTJHOFEHSPVQ DPWFSBHFGPSDIFNJTUSZQSPGFTTJPOBMT t Auto & Homeowners Plus:'PSBVUP IPNF BOEPUIFS QFSTPOBMQSPQFSUZ t Health Insurance Brokerage Service: $POOFDUT ZPVXJUIPWFSCBTJDNFEJDBMJOTVSBODFQMBO PQUJPOT UBJMPSFEUPGJUZPVSMJGFTUZMF t Medical Discount Card: 1SPWJEFTSFEVDFEGFFTPO GSFRVFOUMZVTFEIFBMUISFMBUFETFSWJDFT NPTUPGXIJDI BSFOPUDPWFSFEVOEFSUZQJDBMIFBMUIJOTVSBODFQMBOT t Medicare Supplement: )FMQTQSPUFDUZPVSTBWJOHT BOEGVUVSFQMBOTCZGJMMJOHJOUIFHBQTMFGUCZZPVS .FEJDBSFDPWFSBHF
Sponsored by the Board of Trustees Group Insurance Plans for ACS Members Your Colleagues Working For You! 5PĕOEPVUNPSFBCPVUGFBUVSFT DPTUT FMJHJCJMJUZ SFOFXBCJMJUZ MJNJUBUJPOT BOEFYDMVTJPOT DBMM
Insurance For Life
1.866.679.0811PSWJTJU www.acsmemberinsurance.com/plans
*
Underwritten by New York Life Insurance Company, 51 Madison Avenue, New York, NY 10010, under Policy Form GMR. Brokered and administered by Pearl Insurance, 1200 E Glen Avenue, Peoria Heights, IL 61616.
100050-AP
that for the four-month period, it is still noteworthy, given GAO’s finding that the agency should be inspecting more foreign drug plants than it had been doing. Moreover, FDA appears to be losing ground in India in 2010 compared with earlier years as well. For example, in fiscal 2007, according to GAO, FDA conducted 64 drug plant inspections in India. In fiscal 2010, the agency has completed 41 inspections through May, which puts it on track to complete 70 audits for the year. However, Saxon says FDA traditionally does not schedule inspections in India during the summer months, when heavy monsoon rains make business travel to India impractical. If inspections halt over the summer, then the agency will complete fewer than 70, and possibly fewer than 64. That the number of inspections appears to be dropping raises the question of whether the agency is making progress in improving its diligence abroad. “It’s really not logical that the number of inspections would decrease,” Saxon says. ON THE BASIS OF his review of FDA’s inspection logs, Saxon finds another potential problem with the agency’s work in India. The inspection logs for the two seven-month periods shows that the vast majority of visits are for first-time approval of manufacturing facilities or for inspections linked to the launch of a new product at a facility that FDA has already inspected. The agency has been conducting almost no reinspections of facilities that have already been approved. According to GAO’s 2008 report, reinspections of approved facilities traditionally account for 13% of all inspections. The FDA logs for November 2009 through May 2010 and the same period one year before list only four audits as reinspections of already approved facilities, or the equivalent of 4% of all inspections conducted during that time. This suggests that inspectors have been concentrating on inspecting plants that are about to launch new products into the U.S. and delaying visits to facilities that have already been approved and that are not suspected of having developed manufacturing shortcomings. The logs of inspections conducted in India this year and late last year detail a noticeable drop in the regularity of audits. But more broadly and seriously, they illustrate FDA’s lack of progress in monitoring the country that supplies more generic drugs in the U.S. than any other. ■
Proven Purity. RediSep Rf Gold™ Standard Flash Column (irregular media)
RediSep Rf Gold (spherical media) Tight bands provide maximum resolution allowing greater sample purity or column loading.
Teledyne Isco’s RediSep Rf Gold high performance columns purify closely eluting compounds that don’t typically separate on standard Flash-grade silica gel columns. Our patented*, small spherical flash silica can also handle difficult purifications, such as trace compounds and isomers. Ideal for late eluting or high to medium polarity compounds Sharper peaks and more concentrated fractions Sizes from 4g - 1500g * Foreign Patent granted, U.S. Patent pending.
Tight spherical packing provides minimal band broadening.
Request a sample and see the Gold performance for yourself!
www.isco.com/rfgold
800.228.4373 • 402.464.0231 • www.isco.com •
[email protected] WWW.CEN-ONLINE.ORG
31
JUNE 14, 2010
